Introduction
The FINEARTS-HF trial is a pivotal, large-scale, randomized clinical study evaluating the efficacy and safety of finerenone, a non-steroidal mineralocorticoid receptor antagonist, in patients with heart failure (HF) who have mildly reduced or preserved left ventricular ejection fraction (LVEF ≥40%). Conducted across 653 sites in 37 countries, the trial enrolled 6001 symptomatic HF patients aged 40 years and older. This comprehensive summary categorizes and reviews key findings from multiple prespecified analyses of the trial to provide a detailed understanding of finerenone’s role in treating this patient population.
